NCT06389851 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Saini RK, A Bekhit AE, Roohinejad S, Rengasamy KRR, Keum YS
Chemical Stability of Lycopene in Processed Products: A Review of the Effects of Processing Methods and Modern Preservation Strategies. J Agric Food Chem. 2020 Jan 22;68(3):712-726. doi: 10.1021/acs.jafc.9b06669. Epub 2020 Jan 7.
Wu S, Yuan C, Yang Z, Liu S, Zhang Q, Zhang S, Zhu S
Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study. BMC Med. 2022 Aug 22;20(1):262. doi: 10.1186/s12916-022-02460-8.
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.

Evaluation of the Effects of Tomato Consumption on the Parameters of Hepatic Steatosis, Intestinal Function and on Glucose and Lipid Metabolism in Subjects With NAFLD

Details for clinical trial NCT06389851

Clinical trial NCT06389851 - References